Stockreport

Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer

Kura Oncology, Inc.  (KURA) 
Last kura oncology, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.kuraoncology.com/investor-relations
PDF Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEG [Read more]